Overview
Investment Type
Venture Capital
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 3, 2013 | NovaDigm Therapeutics Closes $14M Series B Financing | NovaDigm Therapeutics, a Grand Forks, North Dakota-based developer of vaccines for fungal and bacterial infections, closed a $14m Series B financing. Backers included new investor RusnanoMedInvest and current investor Domain Associates. Led... |
| Jul 29, 2013 | J&J backs company with cornea inlay to improve impaired focus from aging | In addition to ReVision, AcuFocus has also developed a corneal inlay device. They see a lot of opportunity in the market to surgically improve focus related to age, with an estimated 60 million procedures performed each year. Although there... |
| Dec 19, 2012 | Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty | Other treatment programs in its pipeline that will benefit from the new funding include its REG1 indication for transaortic valve implantation and its treatment for diabetic vasculopathy, a blood vessel disorder, expected to begin Phase 1 c... |
| J&J backs company with cornea inlay to improve impaired focus from aging | One of the effects of aging is reduced vision including presbyopia the loss of the ability to see nearby objects. The current non-surgical approach is to use reading glasses. But companies set on developing a procedure to improve reduced vi... | |
| Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty | In one of the largest financing rounds this year, biopharmaceutical startup Regado Biosciences has raised $51 million to advance its anti-clotting therapeutic through Phase 3 clinical trials. A subsidiary of Russian investment firm Rusnano,... | |
| $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial infections caused by several species of ... |
Reviews 0
FAQ about RusnanoMedInvest
What has the press written about RusnanoMedInvest?
Parsers VC has collected 7 articles mentioning RusnanoMedInvest, among them “NovaDigm Therapeutics Closes $14M Series B Financing” (Oct 3, 2013) and “J&J backs company with cornea inlay to improve impaired focus from aging” (Jul 29, 2013).
Is RusnanoMedInvest still active?
RusnanoMedInvest is probably closed: its latest activity on Parsers VC dates from Oct 4, 2013.